

Market Announcement

18 September 2019

Creso Pharma Limited (ASX: CPH) – Suspension from Official Quotation

Description

The securities of Creso Pharma Limited ('CPH') will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement regarding the proposed acquisition of the Company by PharmaCielo Limited by way of schemes of arrangement pursuant to the Scheme Implementation Agreement announced to ASX on 7 June 2019.

Issued by

Sean Maloney

Adviser, Listings Compliance (Perth)

ABN: 89 609 406 911



18 September 2019

Anjuli Sinniah ASX Compliance Pty Limited Level 40, Central Park, 152-158 St Georges Terrace Perth WA Australia 6000

By email: Anjuli.Sinniah@asx.com.au

Dear Anjuli

Creso Pharma Limited (ASX: CPH) (the '**Company**') requests the voluntary suspension of all quoted securities of the Company, pending an announcement regarding the proposed acquisition of the Company by PharmaCielo Limited by way of schemes of arrangement pursuant to the Scheme Implementation Agreement announced to ASX on 7 June 2019.

The Company requests that its securities remain in suspension until the release of the aforementioned announcement, which is expected to be no later than Friday, 27 September 2019.

The Company is not aware of any reason why the voluntary suspension should not be granted.

Yours sincerely,

Erlyn Dale

Joint Company Secretary